Rhinosinusitis Articles & Analysis
25 news found
"Dupixent is the only treatment available that specifically blocks two key drivers of type 2 inflammation, IL-4 and IL-13, which our trials show plays a major role in childhood asthma, as well as in related conditions such as chronic rhinosinusitis with nasal polyposis and the often co-morbid condition, atopic dermatitis. ...
In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including eosinophilic esophagitis (Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), chronic rhinosinusitis without nasal polyposis (Phase 3), chronic obstructive ...
(Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced positive results of an observational, cohort study using real-world evidence (RWE) data from adult patients with chronic rhinosinusitis (CRS) with or without nasal polyps who underwent endoscopic sinus surgery (ESS). ...
(Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the initiation of the Phase 3 ENLIGHTEN I clinical trial of LYR-210 in adult, surgically naïve chronic rhinosinusitis (CRS) ...
Lyra's lead product candidate, LYR-210, is entering Phase 3 clinical development for the treatment of chronic rhinosinusitis (CRS) as an alternative to primary sinus surgery. Lyra's second product candidate, LYR-220, is entering Phase 2 development and is designed to be an alternative to revision CRS sinus surgery and post-surgical medical management. ...
FESS is used to treat chronic rhinosinusitis, a persistent inflammation of the sinuses that can be debilitating to patients. ...
(Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues will host a virtual event with leading chronic rhinosinusitis (CRS) experts to highlight the Company's LYR-210 and LYR-220 clinical programs on ...
Joanne Rimmer, MBBS, MA, FRCS (ORL-HNS), FRACS, Clinical Associate Professor and Otolaryngologist at Monash University in Melbourne, Australia, and an investigator in the LANTERN study, presented the LANTERN 6-month post-treatment outcomes, which showed continued safety and that about half of treated chronic rhinosinusitis (CRS) patients experienced a durable response six months ...
The manuscript titled, “Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study,” can be accessed online here. ...
New LYR-210 data from the LANTERN 6-month follow-up study and recently completed pharmacokinetic study, will be the subject of oral presentations at ARS, with the pharmacokinetic study selected as a top clinical abstract at the meeting. 28th Congress of European Rhinologic Society Presentations: Title: Long-acting implantable corticosteroid matrix for chronic ...
” One of the major goals of the World Sinus Health Awareness Day inaugural education campaign is to delineate common ailments of the nose and sinus such as allergic and non-allergic rhinitis and acute and chronic rhinosinusitis (CRS) from COVID-19-related symptoms by comparing and differentiating the symptoms of each based on data-driven clinical information in patient ...
Outcomes supported advancing into clinical development for LYRA’s first indication, Chronic Rhinosinusitis, with lead product candidate, LYR-210, currently poised to enter Phase 3 studies Lyra Therapeutics, Inc. ...
Lyra’s lead product candidate, LYR-210, is entering Phase 3 clinical development for the treatment of chronic rhinosinusitis as an alternative to primary sinus surgery. Lyra’s second product candidate, LYR-220 which is entering Phase 2 development, is designed to be a potential preferred alternative to revision sinus surgery and post-surgical medical management. ...
(Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues will host Chronic Rhinosinusitis (CRS) Key Opinion Leader Event on Tuesday, August 31, 2021 from 3:00 p.m. - 4:30 p.m. ...
The complementary product lines and customer base will further Medtronic's efforts to have a positive impact for patients who suffer from chronic rhinosinusitis (CRS). Intersect ENT's PROPEL® and SINUVA® sinus implants are clinically proven solutions that open sinus passageways and deliver an anti-inflammatory steroid to aid in healing. ...
The VenSure Balloon and Cube 4D Navigation Systems are used in procedures that are designed to improve debilitating chronic rhinosinusitis (CRS) symptoms. VirtuEye photo registration is an exclusive and novel, touchless technology that allows for easy 3D facial registration, pinpoint accuracy and improved workflow efficiency for balloon sinus dilation (BSD) procedures and other ...
PROPEL Contour features an innovative hourglass shape, specifically designed for placement in the frontal sinuses (between the eyebrows) following sinus surgery for chronic rhinosinusitis patients. The implant features a low-profile flexible delivery system to make it easier to access areas of the frontal sinus ostia. “Having the ability to accommodate the size and ...
The EXPAND study’s primary objective is to evaluate the efficacy of the Company’s PROPEL® Contour (mometasone furoate) sinus implant when placed in the frontal sinus ostium following in-office balloon dilation in patients with chronic rhinosinusitis (CRS) as compared to balloon sinus dilation alone. Patients will be assessed at various intervals throughout the ...
(Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that the company will present Phase 2 results from the LANTERN study for LYR-210, the company’s lead product candidate for chronic ...
In December, Lyra announced positive topline results from its LANTERN Phase 2 study of LYR-210 for the treatment of Chronic Rhinosinusitis, including: LYR-210 is the first nasal implant to achieve a benefit of up to six months after a single administration in a clinical testing, and the first nasal implant to achieve a benefit in both polyp and non-polyp patients in clinical ...